• Policy
• Legislation to prevent reverse-payment agreements
• by Lee, Jeong-Hwan Oct 4, 2023 05:35am

• Policy
• Myung-in & Hwan-in are launching Fycompa’s generics
• by Lee, Tak-Sun Sep 27, 2023 05:44am

• Policy
• MFDS grants EUA of Moderna’s adapted COVID-19 vaccine
• by Lee, Hye-Kyung Sep 27, 2023 05:44am

• Company
• Padcev can be prescribed at tertiary hospitals in KOR
• by Eo, Yun-Ho Sep 27, 2023 05:44am

• Policy
• Resolving Conflicts in Non-face-to-face Medical treatment
• by Lee, Jeong-Hwan Sep 27, 2023 05:44am

• Policy
• Why did the original Ninlaro voluntarily cut its price 34%
• by Lee, Tak-Sun Sep 27, 2023 05:44am

• Policy
• Madopar triggers bioequivalence test verification requests
• by Lee, Hye-Kyung Sep 26, 2023 05:50am

• Opinion
• [Reporter's view] Paid-in capital increase & bio ventures
• by Lee, Seok-Jun Sep 26, 2023 05:49am

• Company
• Daewon’s Pelubi enters Indonesia with a KRW 4 bil deal
• by Chon, Seung-Hyun Sep 26, 2023 05:49am

• Company
• Luxturna can be prescribed at general hospitals
• by Eo, Yun-Ho Sep 26, 2023 05:49am